ERBB2 and gastric cancer: These clinicopathological findings strongly suggest that HER2-overexpressing gastric cancer liver metastases are a unique clinical entity sharing the same characteristics, for example, morphology (intestinal type), metastatic potential (CXCR4 expression) and gefitinib sensitivity, and therefore, may be a good therapeutic target for gefitinib.